The Scientist : NewsBlog Print: NCI tackles trial enrollment
The Scientist: NewsBlog:
NCI tackles trial enrollment
Posted by Edyta Zielinska
[Entry posted at 22nd July 2009 05:03 PM GMT]

Why does it take so long to complete a clinical trial? One bottleneck that many researchers face is enrolling enough participants to make the study statistically significant.

On Monday (20 July), the National Cancer Institute's Cancer Biomedical Informatics Grid -- aka caBIG -- announced plans to team up with the Susan Love Research Foundation to create a database of 1 million women interested in participating in clinical trials via the Army of Women website. These women, referred to as the Health of Women (HOW) cohort, can then be tapped by epidemiologists at will.

Image: National Cancer Institute
Normally, patient recruitment for a single study involves multiple recruiting clinics and doctors, and in some cases take years to complete. Here, researchers could solicit volunteers through Army of Women. After an investigator has contacted prospective participants, the study would undergo the usual institutional review board (IRB) oversight and receive informed consent from each participating woman.

When I signed up on the database yesterday, I was prompted to fill in my name, year of birth, email address and ethnicity, but was asked for no additional health information. I then clicked a box to receive update emails from the database containing details about upcoming clinical trials, their criteria for participation and what would be required of me as a participant. If I choose to participate, I will receive questionnaires about my health history to fill out online. I'll also receive reminders to update my health information as it changes.

The aim of the project is to allow cancer researchers to "cost-effectively conduct research studies," said Ken Buetow the director of the caBIG program -- an extensive IT infrastructure designed to make data sharing and collaboration easier across cancer researchers worldwide. (Buetow wrote about the caBIG project in our April 2008 issue.)

The service may be inexpensive, but it isn't free. Researchers are charged a fee for each batch of emails they send to potential volunteers -- $1,000 for an email sent to 1,000 or more women in the database, according to the website. Specimen collection, if it is performed at Army of Women collection centers, would incur an additional fee ranging from $10 to $350 per sample, depending on the complexity of the collection procedure. Eventually, said Buetow, the cohort could be expanded to clinical drug trials, but for now, the program is designed only for epidemiological cohort studies.

As of June, some 300,000 women have agreed to be contacted to participate in research and some 11,000 have already been enrolled in research investigations that requested volunteers late last year. caBIG's infrastructure will help disseminate raw data that comes out of the HOW studies, in addition to providing the security encryption to keep participants' health information private, said Buetow. The project could also help "return the research information back to the women" who participate, he said -- though he didn't specify how exactly that would occur.


Related stories:
  • Heading for the BIG time
    [April 2009]
  • caBIG in action
    [April 2009]
  • Preventing cancer
    [22nd September 2003]


  •  

    Rate this article

    Rating: 3.43/5 (7 votes )





    Accessing global population is key
    by John Lewis

    [Comment posted 2009-07-23 09:22:17]
    This is a very good initiative from NCI but to truly accelerate patient recruitment and the drug development process we must look beyond the borders of the United States and access the global population. Cancer is not a U.S-only disease. Research released this week by the Association of Clinical Research Organizations (ACRO) shows that the enrollment time for cancer trials can be reduced by two-thirds - from nearly six years to less than two years - by conducting the research globally. This means, potentially, that a new treatment can be made available four years sooner, saving countless lives. The report also found that safety, ethics and quality in global trials are at the same levels as U.S. trials. The full report can be accessed at www.acrohealth.org/globalization. Thank you.



    Genotype pools needed for drug research
    by Cheryl Soehl

    [Comment posted 2009-07-22 14:29:06]
    Perhaps more important than research by gender is clinical trials by genetic phenotype. When drugs are developed based on a one size fits all model, the minority of people who may be adversely affected are written off as not statistically significant; however, if 100% of a particular genetic minority is affected, the consequences could be disastrous for that group.

    How about establishing a database of possible subjects classified by phenotype for testing drug safety?




    Comment on this blog